February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...

OTTAWA, Ontario, March 19, 2025 (GLOBE NEWSWIRE) -- While levels of social interaction vary across remote, hybrid, and in-person work, where an employee works does not determine workplace loneliness ...

The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating ...

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition.

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

MB-O: Conceptualization, Methodology, Supervision, Writing – review & editing. CO has received travel grants from Lundbeck, which had no bearing on the research of this study. PB has received ...

Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment.